Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 15/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609085 | 0.80 | CCR4 (0.45) | CCR4CCR5EDNRA | |
| SCHEMBL30416654 | 0.80 | CCR4 (0.45) | CCR4CCR5EDNRA | |
| SCHEMBL20399659 | 0.77 | CCR4 (0.35) | CCR4EDNRA | |
| SCHEMBL29364914 | 0.77 | CCR4 (0.43) | CCR4CCR5EDNRA | |
| SCHEMBL14970085 | 0.77 | CCR4 (0.43) | CCR4CCR5EDNRA | |
| SCHEMBL68083 | 0.77 | CCR4 (0.43) | CCR4CCR5EDNRA | |
| SCHEMBL19785488 | 0.76 | APP (0.50) | — | |
| SCHEMBL30296090 | 0.76 | APP (0.50) | — | |
| SCHEMBL19193244 | 0.75 | CCR4 (0.42) | CCR4CCR5EDNRA | |
| SCHEMBL31133084 | 0.75 | CCR4 (0.42) | CCR4CCR5EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709381-A1 | PARP1 INHIBITOR COMPOUNDS | Duke Street Bio Limited (GB) | 2026-03-18 | — | — | EP | disclosed |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-08-28 | — | — | US | disclosed |
| US-12338233-B2 | PD-1/Pd-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| WO-2025029075-A1 | NOVEL BIPHENYL DERIVATIVE AS PD-L1 INHIBITOR | (주)아이랩 | 2025-02-06 | — | — | WO | disclosed |
| EP-4499630-A1 | BCL-XL INHIBITORS | BeiGene, Ltd. (KY) | 2025-02-05 | — | — | EP | disclosed |
| US-20250034128-A1 | BCL-XL INHIBITORS | BEIGENE, LTD. (KY) | 2025-01-30 | — | — | US | disclosed |
| WO-2024256377-A1 | PARP1 INHIBITOR COMPOUNDS | Duke Street Bio Limited (GB) | 2024-12-19 | — | — | WO | disclosed |
| CN-118974033-A | Bcl-xL inhibitors | 百济神州有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240336601-A1 | 4-PHENYL-INDOLE DERIVATIVES AND RELATED USES | CHULALONG UNIVERSITY (TH) | 2024-10-10 | — | — | US | disclosed |
| CN-118084940-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20160326143-A1 | COMPOUNDS AND USES | ASTRAZENECA AB (SE) | 2016-11-10 | — | — | US | disclosed |
| WO-2016177845-A1 | CYCLOPROPANE CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL USES THEREOF | ASTRAZENECA AB (SE) | 2016-11-10 | — | — | WO | disclosed |
| US-20160326143-A1 | COMPOUNDS AND USES | ASTRAZENECA AB (SE) | 2016-11-10 | — | — | US | disclosed |
| US-20160326143-A1 | COMPOUNDS AND USES | ASTRAZENECA AB (SE) | 2016-11-10 | — | — | US | disclosed |
| WO-2016177845-A1 | CYCLOPROPANE CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL USES THEREOF | ASTRAZENECA AB (SE) | 2016-11-10 | — | — | WO | disclosed |
| EP-2491026-A1 | NOVEL HETEROARYL IMIDAZOLES AND HETEROARYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS | Pfizer Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20120202787-A1 | Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators | PFIZER INC. | 2012-08-09 | — | — | US | disclosed |
| US-20120202787-A1 | Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators | PFIZER INC. | 2012-08-09 | — | — | US | disclosed |
| US-20120202787-A1 | Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators | PFIZER INC. | 2012-08-09 | — | — | US | disclosed |
| WO-2011048525-A1 | NOVEL HETEROARYL IMIDAZOLES AND HETEROARYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202787-A1 | Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators | BACE1, BACE2, GSAP | CCR4 4864/4885CCR5 3843/4885EDNRA 2997/4885 |
| US-12338233-B2 | PD-1/Pd-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | CCR4 960/4885CCR5 403/4885EDNRA 2239/4885 |
| US-20250034128-A1 | BCL-XL INHIBITORS | BCL2, BCL2L1, BCL2L10 | CCR4 3798/4885CCR5 3066/4885EDNRA 4075/4885 |
| US-20240336601-A1 | 4-PHENYL-INDOLE DERIVATIVES AND RELATED USES | PDCD1, PDCD1LG2, CD274 | CCR4 1229/4885CCR5 315/4885EDNRA 1063/4885 |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CCR4 960/4885CCR5 403/4885EDNRA 2239/4885 |
| US-20160326143-A1 | COMPOUNDS AND USES | LTC4S, LTB4R2, LTA4H | CCR4 1098/4885CCR5 940/4885EDNRA 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.